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Abstract
Hypertension is a hemodynamic disorder and one of the most important and well-estab-
lished risk factors for vascular diseases such as stroke. Blood vessels exposed to chronic
shear stress develop structural changes and remodeling of the vascular wall through many
complex mechanisms. However, the molecular mechanisms involved are not fully under-
stood. Hypertension-susceptible genes may provide a novel insight into potential molecular
mechanisms of hypertension and secondary complications associated with hypertension.
The aim of this exploratory study was to identify gene expression differences in the middle
cerebral arteries between 12-week-old male spontaneously hypertensive rats and their nor-
motensive Wistar-Kyoto rats using an Affymetrix whole-transcriptome expression profiling.
Quantitative PCR and western blotting were used to verify genes of interest. 169 genes
were differentially expressed in the middle cerebral arteries from hypertensive compared to
normotensive rats. The gene expression of 72 genes was decreased and the gene expres-
sion of 97 genes was increased. The following genes with a fold difference1.40 were veri-
fied by quantitative PCR; Postn, Olr1, Fas, Vldlr, Mmp2, Timp1, Serpine1, Mmp11, Cd34,
Ptgs1 and Ptgs2. The gene expression of Postn, Olr1, Fas, Vldlr, Mmp2, Timp1 and Ser-
pine1 and the protein expression of LOX1 (also known as OLR1) were significantly
increased in the middle cerebral arteries from spontaneously hypertensive rats compared to
Wistar-Kyoto rats. In conclusion, the identified genes in the middle cerebral arteries from
spontaneously hypertensive rats could be possible mediators of the vascular changes and
secondary complications associated with hypertension. This study supports the selection of
key genes to investigate in the future research of hypertension-induced end-organ damage.
Introduction
Hypertension is a hemodynamic disorder and one of the most important and well-established
risk factors for cardiovascular diseases and stroke. Essential hypertension is defined as blood
pressure of 140/90 mmHg or above of unknown cause [1]. The blood pressure is not controlled
in nearly 50% of hypertensive patients due to no obvious symptoms of essential hypertension
[2,3]. The consequence is a large group of patients in high risk of secondary complications.
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During essential hypertension, the blood vessels are exposed to chronic shear stress which
leads to structural changes and remodeling of the vascular wall. Hypertension causes vascular
remodeling through many different and complex mechanisms [4,5], but the underlying gene
expressions are not fully understood. To gain a better understanding of these mechanisms, this
exploratory study is to our knowledge the first to identify gene expression differences in the
middle cerebral arteries (MCAs) between spontaneously hypertensive rats (SHRs) and their
normotensive Wistar-Kyoto rats (WKY rats) using an Affymetrix whole-transcriptome expres-
sion profiling (termed whole-genome microarray gene-expression profiling). A whole-genome
microarray gene-expression profiling is a useful tool to permit an unbiased selection of genetic
targets of hypertension and potential secondary complications associated with hypertension.
Our unique focus on the MCAs is important, since hypertension is a vascular disease and a
risk factor of other cerebrovascular diseases such as stroke. It also contributes to elevated
vascular resistance by changes in the vascular wall, and pial arteries such as the MCAs contrib-
ute to the cerebrovascular resistance [6]. Especially the regions of arterial branching are more
susceptible to altered shear stress due to the greater effect of hemodynamic forces such as
mechanical stretch [7].
Hypertension induces excessive stress on the vascular wall over time, causing alterations in
the wall thickness and composition. Implicated alterations are growth and migration of
smooth muscle cells (SMCs), endothelial dysfunction, inflammation, cell death and synthesis
and degradation of the extracellular matrix (ECM). These alterations as well as humoral factors
modify the mechanical and hemodynamic properties of the arteries [5]. It is acknowledged,
that the alterations for example enhance the wall thickness, reduce the lumen of the artery or
lead to arterial stiffening [8]. As a consequence of all these hypertension-induced changes in
the vascular wall, the genes and their transcriptomic products are up- or downregulated.
The aim of this exploratory study was to investigate genes involved in the vascular changes
associated with hypertension. This study contributes to the current knowledge of the molecu-
lar mechanisms that are involved in hypertension and in the potential secondary complica-
tions associated with hypertension.
Materials and methods
Ethics
All experiments were carried out in strict accordance with the guidelines from the European
Community Council directive (2010/63/EU) for Protection of Vertebrate Animals Used
for Experimental and other Scientific Purposes and were approved by the Danish Animal
Experiments Inspectorate (Permit Number: 2014-15-0201-00042). The study complies with
the ARRIVE guidelines (Animal Research: Reporting In Vivo Experiments). All surgeries
were performed under isoflurane anesthesia, and all efforts were made to minimize
suffering.
Animals
12-week-old male SHRs (257-311g) and their normotensive control WKY male rats (299-
340g) were obtained from Charles River (Charles River laboratories, Sulzfeld, Germany). The
SHR is an animal model of essential hypertension [9] and develops hypertension at 4 weeks of
age [10] why this animal model can provide useful information and implications of pathophys-
iological processes in humans. The rats were housed with a 12 hours light/dark cycle and pro-
vided with standard rat chow and tap water ad libitum.
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Blood pressure measurement and harvest of arteries
The rats were anaesthetized with 2.5% isoflurane in N2O/O2 (70:30) followed by cannulation
of the tail artery to record the MABP for five minutes. This is a direct measurement of the
blood pressure [11]. The rats were sacrificed by decapitation, and the MCAs were carefully dis-
sected from the brain and stripped of connective tissue and blood in ice-cold sodium Krebs
buffer (NaCl 119mM, NaHCO3 15mM, KCl 4.6mM, MgCl2 1.2mM, NaH2PO4 1.2mM, CaCl2
1.5mM and glucose 5.5mM) oxygenated with 5% CO2 in O2. The tissue was snap frozen on
dry ice and kept at -80˚C until the preparation of RNA extraction.
RNA preparation
Total RNA extraction was prepared in the same way for the whole-genome microarray gene-
expression profiling and quantitative PCR (qPCR). Tissue from one MCA was homogenized
on dry ice 3x20sec in lysis buffer (ML buffer) from the NucleoSpin miRNA isolation kit
(Macherey-Nagel, Germany) using a FastPrep-24™ 5G instrument (MP Biomedicals, USA).
Lysing matrix D tubes containing 1.4mm ceramic spheres (MP Biomedicals, USA) were
used for tissue homogenization. Total RNA extraction was carried out using the NucleoSpin
miRNA isolation kit according to the manufacturers’ protocol. The RNA was eluted in 30μl
RNAse free water. Total RNA concentration was measured using the NanoDrop 2000 UV-Vis
spectrophotometer (ThermoFisher Scientific, MA, USA), whereupon a ratio of sample absor-
bance at 260nm and 280nm in the range of 1.7 to 2.1 was acceptable. The integrity of the RNA
was measured using the Agilent 2100 Bioanalyzer (Agilent Technologies, CA, USA), where the
acceptable RNA integrity number was7.
Whole-genome microarray gene-expression profiling
Affymetrix whole-transcriptome expression profiling was processed by Swegene centre for
integrative biology (SCIBLU) genomics, Affymetrix unit at Lund University, Sweden.
A total of 100ng RNA was primed with primers containing a T7 promoter sequence to
synthesize first-strand cDNA. The single-stranded cDNA was then converted to a double-
stranded cDNA and used as a template for the in vitro transcription (IVT) to synthesize anti-
sense RNA (also called complimentary RNA or cRNA) using a T7 RNA polymerase. This
procedure is known as the Eberwine or RT-IVT method [12]. The cRNA was purified by
removing enzymes, salts, inorganic phosphates and unincorporated nucleotides and quantified
for the 2nd-cycle single-stranded cDNA synthesis, from where sense-strand cDNA (ss-cDNA)
was synthesized. RNase H was used to hydrolyze the cRNA template leaving ss-cDNA. After
hydrolysis, the ss-cDNA was purified to remove enzymes, salts and unincorporated dNTPs
tfor fragmentation and labelling. ss-cDNA was fragmented by uracil-DNA glycosylase and
apurinic/apyrimidinic endonuclease-1 at the unnatural dUTP residues that breaks the DNA
strand. The fragmented ss-cDNA was labelled by terminal deoxynucleotidyl transferase using
the Affymetrix proprietary DNA Labelling Reagent that is covalently linked to biotin allona-
mide triphosphate. The fragmented and biotin-labelled ss-cDNA was added to a hybridization
cocktail onto the Affymetrix GeneChip rat gene 2.0 ST arrays followed by hybridization for 16
hours at 45˚C in an Affymetrix Gene Chip Hybridization 645 oven. The array was washed and
stained on the GeneChip Fluidics Station 450 using the appropriate fluidics script before being
inserted onto an Affymetrix autoloader carousel and scanned using the Affymetrix GeneChip
scanner 3000 7G.
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cDNA synthesis and qPCR
66ng RNA was synthesized to cDNA using the RT2 First Strand Kit (Qiagen, USA) according
to the manufacturer’s protocol. qPCR was performed in a 10μl reaction volume containing
TaqMan 2x universal PCR master mix (ThermoFisher Scientific, MA, USA), 20x TaqMan
gene expression assay, RNAse free water and 2μl cDNA using the QuantStudio 12K Flex real-
time PCR system (ThermoFisher Scientific, MA, USA) with ROX as a passive reference. A no-
template control with RNAse free water instead of cDNA was used as negative control for all
TaqMan gene expression assays. An inter-plate control for all TaqMan gene expression assays
was used to control the thermal cycling between plates. All TaqMan gene expression assays
were pipetted in triplicates for each sample. Taqman gene expression assays, for the following
genes, were purchased from ThermoFisher Scientific, MA, USA: periostin, osteoblast specific
factor (Postn) (Rn01494627_m1), oxidized low density lipoprotein (lectin-like) receptor 1
(Olr1) (Rn00591116_m1), fas, TNF receptor superfamily member 6 (Fas) (Rn00685720_m1),
very low density lipoprotein receptor (Vldlr) (Rn01498167_m1), matrix metallopeptidase 2
(Mmp2) (Rn01538170_m1), tissue inhibitor of metallopeptidase 1 (Timp1) (Rn00587558_m1),
serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1, member 1
(Serpine1) (Rn01481341_m1), cd34 molecule (Cd34) (Rn_03416140_m1), prostaglandin-
endoperoxide synthase 1 (Ptgs1) (Rn00566881_m1), Ptgs2 (Rn01483828_m1), Mmp11
(LOC103694874), glyceraldehyde-3-phosphate dehydrogenase (Gapdh) (Rn01749022_g1),
actin beta (Actb) (Rn00667869_m1). Gapdh and Actb were used as reference genes to normal-
ize the mRNA levels. The thermal cycling condition included an initial denaturation step at
50˚C for 2min and 95˚C for 10min followed by 45 PCR cycles at 95˚C for 15sec and 60˚C for
1min.
Western blotting
Cerebral arteries from two rats were pooled and sonicated 3x20 pulses (output 30) on ice
in RIPA buffer containing phosphatase inhibitor (Sigma-Aldrich) and protease inhibitor
(Sigma-Aldrich). For further denaturation the samples were kept at -80˚C for 30 min and
then centrifuged at 14.000rpm for 10min at 4˚C. The protein concentration in the superna-
tant was determined using the DC protein assay kit II (Bio-Rad) with a protein standard II
(Bio-Rad) of bovine serum albumin as a standard curve. The samples were measured on the
Infinite M200 (Tecan) with a wavelength of 750nm. 14μg protein was calculated according to
the protein concentration, and LDS buffer (Expedeon), DTT (Expedeon) and milliQ water
were added before the samples were boiled at 95˚C for 5 min. The samples were loaded on a
4–20% SDS precast gel (Expedeon) and run at 180V for 70 min. The proteins were trans-
ferred to a nitrocellulose membrane (GE Healthcare, Amersham 0.2 NC) at 150V and
350mAmp for 70 min, whereupon the membrane was blocked for unspecific binding for one
hour at room temperature in TBS-T buffer (TBS + 1% Tween 20) containing 2% ECL prime
blocking agent (GE Healthcare, Amersham). The membrane was incubated over night at 4˚C
with rabbit polyclonal anti-lectin-like oxidized low density lipoprotein receptor 1 (LOX1)
antibody (Abcam, ab60178, Lot number GR159762-5, synthetic peptide near the N-terminus
of human Lox-1, AB_943982) diluted 4:1000 (LOX1 is also known as OLR1). Jurkat cells
(gift from senior researcher Birgitte Rahbek Kornum, Department of Clinical Biochemical,
Glostrup Research Institute, Rigshospitalet Glostrup) were used as a running control, and
monoclonal anti-β-Actin-Peroxidase produced in mouse (Sigma A3854, batch number
026M4820V, N-terminal sequence: Ac-Asp-Asp-Asp-Ile-Ala-Ala-Leu-Val-Ile-Asp-Asn-Gly-
Ser-Gly-Lys conjugated to KLH, AB_262011) diluted 1:50.000 was used as a reference
antibody.
Gene expression in the middle cerebral arteries from hypertensive rats
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The following day the membrane was incubated with a horseradish peroxidase (HRP)
conjugated secondary antibody for one hour at room temperature; anti-rabbit IgG HRP (Cell
Signaling #7074) diluted 1:2000. The membrane was stripped (ReBlot Plus Strong from Milli-
pore) for 8min at room temperature, blocked and incubated one hour at 4˚C with the β-
ACTIN antibody. This antibody was developed with no secondary antibody, since it already
contains HRP.
All antibodies were diluted in TBS-T buffer containing 2% ECL prime blocking agent.
Proteins were detected using the ECL select western blotting detection reagent (GE Health-
care, Amersham) and visualized in a Fujifilm LAS-4000 Luminiscent Image Analyser.
Statistical methods
Blood pressure and body weight. In total 35 rats (WKY, n = 17 and SHR, n = 18) were
used for the whole-genome microarray gene-expression profiling, qPCR and western blotting.
No power calculation was used to determine sample size. A two-tailed Mann-Whitney test was
used for the statistical analysis of MABP and body weight using GraphPad Prism 5. Data is
expressed as median ± interquartile range (IQR). P-value <0.05 is considered statistical
significant.
Whole-genome microarray gene-expression profiling. In total 10 rats (WKY rat, n = 5
and SHR, n = 5) were used for the whole-genome microarray gene-expression profiling. Basic
Affymetrix GeneChip and experimental quality analyses were performed using the Expression
Console Software v1.1.2, and the Robust Multi-array analysis method was used for probe sum-
marization and data normalization (quantile normalization and log transformation) using
v1.4.1.46. Data filtration was done for probe sets having a value less than the median values of
the negative control in 80% of total samples. Significance analysis of microarrays (SAM) was
performed using the TMEV v4.0 software to identify significantly differentially expressed
genes between groups (q = 0, termed differentially expressed genes) [13]. The q-values repre-
sent False Discovery Rate (FDR) adjusted p-values, for which q = 0 denotes the statistical sig-
nificant level. The fold difference (FD) is a measure describing how much a quantity changes
going from an initial to a final value. If the FC is positive, the gene expression is increased in
the MCAs from SHRs compared to WKY rats, and if it is negative, the gene expression is
decreased in the MCAs from SHRs compared to WKY rats.
Gene ontology (GO) overrepresentation analysis. All differentially expressed genes
(q = 0) in the MCAs from SHRs compared to WKY rats were included in the GO overrepre-
sentation analysis. Information of genes annotated to the ontologies was extracted from the
GO database using BiomaRt v2.26.1 [14,15]. GO terms with5 annotated genes were
excluded from the analysis. P-values for each GO term were calculated by a right-tailed Fisher’s
exact tests for count data and adjusted for multiple testing. GO terms with FDR-adjusted
p-values <0.05 are considered statistical significant.
qPCR. In total 13 rats (WKY rat, n = 6 and SHR, n = 7) were used for the qPCR experi-
ments. These rats were not the same rats used in the whole-genome microarray gene-expres-
sion profiling. The threshold cycle (Ct) values refer to the number of PCR cycles, where the
hydrolysis probe begins to fluoresce. Ct values were determined using the QuantStudio 12K
Flex software (ThermoFischer Scientific, MCA, USA), and the technical triplicates were
averaged. Automatic background fluorescence, thresholds of the samples, no-template con-
trol and inter-plate control were checked. Adjustment of the averaged Ct values of each Taq-
Man gene expression assays were adjusted relative to its inter-plate control. ΔCt (Ct, sample −
Ct, average of references) values are plotted on the y-axe in the graphs by a logarithmic scale. The
figures are presented as a scatter plot expressed as median ± IQR, and n represents to the
Gene expression in the middle cerebral arteries from hypertensive rats
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number of rats. A two-tailed Mann-Whitney test was used for the statistical analysis using
GrapPad Prism 5. P-value <0.05 is considered statistical significant.
Western blotting. In total 12 rats were used for the western blotting experiments. The
cerebral arteries from two rats were pooled into one sample (WKY rat, n = 3 and SHR, n = 3).
The samples were run twice at different days and normalized to Jurkat cells and β-ACTIN. A
two-tailed Mann-Whitney test was used for the statistical analysis using GraphPad Prism 5.
Data is expressed as median ± IQR, and n represents the number of rats. P-value <0.05 is con-
sidered statistical significant.
Results
Blood pressure and body weight
MABP was significantly higher in 12-week-old SHRs (155 (147–164) mmHg) compared to
the age-matched WKY rats (108 (103–114) mmHg) (P<0.0001), and the body weight was
significantly lower in SHRs (279 (263–292) g) compared to WKY rats (312 (309–332) g)
(P<0.0001).
Whole-genome microarray gene-expression profiling
In total 14,150 probe-set IDs with a gene accession number were detected, and 169 genes were
differentially expressed (q = 0) in MCAs from SHRs compared to WKY rats (S1 Table). Out
of 169 genes, the expression of 72 genes was decreased and the expression of 97 genes was
increased in MCAs from SHRs compared to WKY rats. Using the GO overrepresentation anal-
ysis, all the differentially expressed genes (169 genes) were classified into two GO ontologies
named biological process and cellular component. Biological process was further subdivided
into one GO term named positive regulation of gene expression, and cellular component was
further subdivided into three GO terms named extracellular region, extracellular matrix and
extracellular space (Fig 1).
We decided to proceed with the genes from the GO ontology named cellular component
with a FC1.40 (16 individual genes) (Table 1), since they are related to the extracellular part
of the MCAs and might be implicated in the vascular changes associated with hypertension.
More specific, we selected Fas and Cd34 from the GO term named extracellular region and
Mmp2, Serpine1, Timp1 and Postn from the GO term named extracellular matrix and Vldlr
from the GO term named extracellular space. Mmp2, Timp1 and Postn were also expressed in
the GO term named extracellular space and Serpine1 in the GO term named extracellular
region. This is another reason, why we proceeded with the GO ontology named cellular
component.
Additional to the GO overrepresentation analysis, the putative function of the genes with
a FC1.40 (90 genes) from the whole-genome microarray gene-expression profiling was
investigated by a literature search using PubMed. Apart from Mmp11 which is a matrix metal-
loproteinases as Mmp2 we selected Ptgs1, Ptgs2 and Olr1 due to their possible relation to the
vascular changes associated with hypertension.
The eleven genes verified by qPCR are illustrated in a volcano plot in Fig 2 and in a heat
map in Fig 3.
qPCR. We examined the gene expression of Gapdh and Actb to verify, that the reference
genes were stable between groups. The Ct values between SHRs and WKY rats for both genes
were not statistical significant (Gapdh: SHRs, 25.8 (25.7–26.0); WKY rats 25.9 (25.7–26.0),
P = 0.2662. Actb: SHRs, 23.6 (23.1–23.8); WKY rats 23.5 (23.1–23.8), P = 0.6109).
We decided to verify differentially expressed genes with a FC1.40 in MCAs from SHRs
compared to WKY rats due to a low template concentration, and to be sure to detect the gene
Gene expression in the middle cerebral arteries from hypertensive rats
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expression above the detection limit (Ct value >35). The following eleven genes were chosen
for verification with qPCR: Postn, Olr1, Fas, Vldlr, Mmp2, Timp1, Serpine1, Mmp11, Cd34,
Ptgs1 and Ptgs2 (S2 Table). The verification was done on different RNA preparations than
used in the whole-genome microarray gene-expression profiling to verify the technical process
and the biological variation. The ΔCt values of Postn, Olr1, Fas, Vldlr, Mmp2, Timp1 and Ser-
pine1 were significantly increased in MCAs from SHRs compared to WKY rats (S1 Fig,
Table 2). There was no change in the ΔCt values of Cd34, Ptgs2 and Mmp11 between the MCAs
from SHRs and WKY rats (S2 Fig, Table 2). A reason for this could be the big variation
between the samples in both the WKY and SHR group.
The Ptgs1 gene was not expressed above the detection limit, and it was not possible
to increase the template concentration (data not shown). Of the eleven genes verified by
qPCR, seven genes (Postn, Olr1, Fas, Vldlr, Mmp2, Timp1 and Serpine 1) had similar gene
expression pattern as in the whole-genome microarray gene-expression profiling. These
genes will be discussed according to their relation to the vascular changes associated with
hypertension.
Fig 1. GO overrepresentation analysis network. Network of the differentially expressed genes (q = 0) in the MCAs
from SHRs (n = 5) compared to WKY rats (n = 5).
https://doi.org/10.1371/journal.pone.0184233.g001
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Western blotting
Since Olr1 is an important scavenger receptor with a functional role in hypertension and
stroke, the protein level was examined. In addition, it was one of the genes verified by qPCR
with the lowest p-value (P-value = 0.0079) between the MCAs from SHRs and WKY rats. The
result revealed, that LOX1 protein level was significantly increased in cerebral arteries from
SHRs (1.8 (1.4–4.1)) compared to WKY rats (1.2 (1.1–1.6)) (Fig 4, S3 Fig).
Discussion
In this study, we used a broader approach to understand the molecular mechanisms of the vas-
cular changes in the MCAs due to hypertension by the whole-genome microarray gene-
expression profiling. We demonstrated an increased gene expression of Postn, Fas, Vldlr,
Mmp2, Timp1, Serpine1 and Olr1 as well as an increased LOX1 protein expression in the
MCAs from hypertensive rats (hypertensive cerebral arteries) compared to normotensive rats
(normotensive cerebral arteries). Vascular morphology of the cerebral arteries is already
altered in the early stage of hypertension [16]. According to the GO overrepresentation analy-
sis Postn, Fas, Vldlr, Mmp2, Timp1 and Serpine1 are related to the extracellular part of the
hypertensive cerebral arteries. Changes in the ECM components of the vascular wall have
Table 1. Differentially expressed genes from the GO ontology named cellular component with a fold difference1.40.
GO name
(GO id)
Adjusted P-value
(FDR)
Gene Description FD
Extracellular matrix
(GO:0031012)
Postn Periostin, osteoblast specific factor 2.634
Cilp Cartilage intermediate layer protein, nucleotide pyrophosphohydrolase 2.215
0.0017 Serpine1 Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 1.835
Timp1 TIMP metallopeptidase inhibitor 1 1.588
Pcsk6 Proprotein convertase subtilisin/kexin type 6 1.533
Serpine2 Serpin peptidase inhibitor, clade E, member 2 1.482
Mmp2 Matrix metallopeptidase 2 1.465
Extracellular region
(GO:0005576)
Penk Proenkephalin 2.155
Serpine1 Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 1.835
0.0244 Fgf7 Fibroblast growth factor 7 1.780
Cd34 Cd34 molecule 1.658
Fas Fas (TNF receptor superfamily, member 6) 1.550
Serpine2 Serpin peptidase inhibitor, clade E, member 2 1.482
Prrg4 Proline rich Gla (G-carboxyglutamic acid) 4 (transmembrane) 1.430
Extracellular space
(GO:0005615)
Postn Periostin, osteoblast specific factor 2.634
Cilp Cartilage intermediate layer protein, nucleotide pyrophosphohydrolase 2.215
Fap Fibroblast activation protein, alpha 1.956
Serpine1 Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 1.835
0.0488 Serpind1 Serpin peptidase inhibitor, clade D (heparin cofactor), member 1 1.772
Timp1 TIMP metallopeptidase inhibitor 1 1.588
Mrpl18 Mitochondrial ribosomal protein L18 1.536
Pcsk6 Proprotein convertase subtilisin/kexin type 6 1.533
Serpine2 Serpin peptidase inhibitor, clade E, member 2 1.482
Mmp2 Matrix metallopeptidase 2 1.465
Vldlr Very low density lipoprotein receptor 1.440
GO, gene ontology; FDR, false discovery rate; FD, fold difference.
https://doi.org/10.1371/journal.pone.0184233.t001
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previously been demonstrated in hypertension, since the cells synthesize the ECM to provide
structural support to the artery [17]. An excess of ECM products have also been shown in
other vascular diseases such as stroke [18]. Olr1 was also found to be related to the vascular
changes associated with hypertension. In the cerebral arteries, a correlation between the fol-
lowing genes and the vascular changes besides the secondary complications associated with
hypertension is therefore suggested.
We demonstrated an increased gene and protein expression of the scavenger receptor Olr1
(also known as the lectin-like oxidized low density lipoprotein receptor 1 (Lox1)) in the hyper-
tensive cerebral arteries which correlates with previous findings [19,20]. The basal expression
of Olr1 in the vascular wall is usually very low, but it can be induced by pro-inflammatory and
mechanical stimuli such as hypertension [21]. The same is suggested by our results due to the
basal Olr1 expression in normotensive cerebral arteries and the increased expression in hyper-
tensive cerebral arteries. The receptor is primarily found to bind, internalize and degrade oxi-
dized LDL (oxLDL) which is a mechanism linked to an inflammatory response [21].
Hypertension and stroke are both associated with increased levels of inflammatory markers
reflecting the inflammatory process in both pathologies [22,23]. Polymorphism of the Olr1
gene has also been associated with the risk of developing left ventricular hypertrophy in
patients with essential hypertension, and hypertrophic remodeling of the vascular wall is a
Fig 2. Volcano plot. Red and blue dots are differentially expressed genes (q = 0) in the MCAs from SHRs (n = 5) compared to WKY rats (n = 5). Red
dots are genes verified by qPCR.
https://doi.org/10.1371/journal.pone.0184233.g002
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characteristic for hypertension [24]. The increased Olr1 expression in hypertensive cerebral
arteries might indicate vascular remodeling and inflammation which also suggest a link
between hypertension and the risk of developing secondary complications such as stroke. This
is supported by clinical data, since Olr1 was found in early atherosclerotic plaque from ische-
mic patients [25] and correlated to the risk of having a stroke using a meta-analysis [26].
Fig 3. Heat map of genes verified by qPCR. Box color and color key show the expression level differences between WKY rats (n = 5) and
SHRs (n = 5), reported as the Z score, which is the scaled gene expression measurement (scaled row-wise, mean = 0, SD = 1). As expected,
WKY rats and SHRs are grouped separately due to distinct expression patterns between groups. The numbers in the boxes represent
normalized expression values of each gene for each rat.
https://doi.org/10.1371/journal.pone.0184233.g003
Table 2. Expression levels of genes verified by qPCR.
Gene WKY rats SHRs P-value
Median (IQR) Median (IQR)
Postn 7.5 (7.3–8.2) 6.1 (5.8–6.8) 0.0159
Olr1 10 (9.8–10.3) 7.5 (6.4–7.7) 0.0079
Fas 5.7 (5.6–6.0) 5.2 (5.1–5.4) 0.0079
Vldlr 6.0 (5.7–6.4) 4.9 (4.6–5.3) 0.0079
Mmp2 6.4 (6.3–6.6) 5.8 (5.7–6.3) 0.0247
Timp1 5.7 (5.6–6.0) 5.1 (5.0–5.2) 0.0022
Serpine1 5.2 (5.1–5.4) 3.6 (3.5–3.8) 0.0079
Cd34 4.9 (4.4–5.2) 4.9 (4.5–5.3) 1.0000
Ptgs2 6.2 (5.9–6.7) 5.6 (5.5–6.2) 0.3095
Mmp11 8.2 (8.0–8.3) 8.1 (7.8–8.7) 0.8726
IQR, interquartile range.
https://doi.org/10.1371/journal.pone.0184233.t002
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Interestingly, Olr1 has been suggested to increase Mmp2 expression in human umbilical
vein endothelial cells [27] indicating a connection between their increased gene expression in
hypertensive cerebral arteries.
The occurrence of Postn in the ECM, by the GO overrepresentation analysis, can be
explained by its role as a soluble ECM protein. It mediates proliferation and migration of
SMCs, and Postn expression has previously been correlated with the proliferative state of
neointimal SMCs in the balloon-injured vascular wall [28]. The gene is also interesting in a
clinically perspective, since Postn expression was increased in lung tissue from patients with
pulmonary arterial hypertension [29]. These data combined suggests that the increased Postn
expression in hypertensive cerebral arteries indicates SMC proliferation and thereby vascular
changes in response to hypertension.
Increased Mmp2 expression in hypertensive cerebral arteries may induce vascular changes
by degrading proteins of the ECM [4]. A connection between increased Mmp2 expression and
vascular remodeling of the aorta has previously been suggested in hypertensive rats [30].
Mmp2 is secreted constitutively from vascular SMCs [31] which explains the basal gene
expression in normotensive cerebral arteries. The increased gene expression in hypertensive
cerebral arteries is supported by an increased expression and activation of Mmp2 by mechani-
cal stretch such as hypertension in human aortic SMCs [32]. However, the plasma level of
Mmp2 from hypertensive patients has been demonstrated to be both increased and decreased
[33,34], why its specific role in hypertension is yet to be elucidated.
On the other hand, remodeling of ECM by Mmps affects the migration and proliferation of
SMCs and thereby the formation of a neointima [31,35] that ultimately occlude the affected
Fig 4. LOX1 protein level. LOX1 (also known as OLR1) expression in the cerebral arteries from SHRs
compared to WKY rats and representative blot of LOX1 and β-ACTIN. Data is normalized to Jurkat cells and
β-ACTIN. Data is expressed as median ± interquartile range, and n represents the number of rats. P-value
<0.05 is considered statistical significant.
https://doi.org/10.1371/journal.pone.0184233.g004
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arteries. Mmp2 expression has also been confirmed in ischemic brain tissue [36]. These data
suggests a link between changes in the ECM and SMCs in response to hypertension and the
susceptibility to secondary complications.
Mmp2 secretion was reported to be induced by increased Postn expression [37] which
could be a connection between the increased expression of both genes in hypertensive cerebral
arteries. Their role in the ECM modulation and SMC migration and proliferation may indicate
vascular remodeling in response to hypertension that entails end-organ damage.
The increased Timp1 expression in hypertensive cerebral arteries could be a mechanism to
counterbalance the increased Mmp2 expression, due to its role as Mmp inhibitor [38]. Timps
do not have a high specificity for any particular Mmps, but it is suggested that Timp2 preferen-
tial binds Mmp2, and Timp1 binds Mmp9 [39]. This might explain why the gene expression of
Mmp9 is not increased in hypertensive cerebral arteries. However, in both hypertensive and
normotensive cerebral arteries the Timp1 expression (SHRs, 5.1 (5.0–5.2); WKY rats 5.7 (5.6–
6.0)) was significantly increased compared to the Mmp2 expression (SHRs, 5.8 (5.7–6.3),
P = 0.0022; WKY rats 6.4 (6.3–6.6), P = 0.0087) suggesting that Timp1 might suppress the
Mmp2 activity. The correlation between Timp1 and Mmp2 expression could also be a reason
for the discrepancy between the measured plasma levels of Mmp2 from hypertensive patients.
On the other hand, Mmp2 is a member of the gelatinases which digest collagen in the sub-
endothelial basement membrane [4]. Suppressed Mmp2 expression by Timp1 could lead to
increased collagen accumulation and thereby vascular remodeling of the hypertensive cerebral
arteries. In a systematic review and meta-analysis, only Timp1 levels were greater in hyperten-
sive than normotensive patients, whereas both Timp1 and Mmp2 levels were greater in hyper-
tensive patients with heart failure than hypertensive patients without heart failure. It was
therefore suggested, that both Timp1 and Mmp2 were potential plasma biomarkers of cardio-
vascular remodeling in response to hypertension [38].
The increased Serpine1 expression in hypertensive cerebral arteries might be a protecting
mechanism against ECM proteolysis, since Serpine1 (also known as plasminogen activating
inhibitor type 1) inhibits plasminogen activators such as urokinase-type plasminogen activator
(uPA). The plasminogen activators converts plasminogen to plasmin which is essential for
ECM degradation and activation of the fibrinolysis [40]. Consequently, Serpine1 plays a role
in maintaining the fibrin blood clot and the risk of having a stroke [41,42]. In relation to its
role in hypertension and ECM degradation, Serpine1 augmented intima-media thickness con-
tributing to endothelial dysfunction in carotid arteries from hypertensive patients [43]. This
could also be a reason for the increased Serpine1 expression in hypertensive cerebral arteries.
Vldlr was previously found to play a role in intimal thickening [44] and to regulate uPA-
Serpine1 complexes [45], which could be a connection between the increased expression of
both genes in the hypertensive cerebral arteries.
Fas is a cell surface death receptor, that induces SMCs apoptosis [46]. Fas is therefore sug-
gested to be an apoptotic marker in the hypertensive cerebral arteries. Apoptosis is implicated
in different vascular pathologies such as hypertension [47,48], and has been associated with
vascular remodeling of mesenteric arteries from hypertensive rats with the same age as the rats
in our study [49]. This study is to our knowledge the first to demonstrate increased Fas expres-
sion in hypertensive cerebral arteries, but it has also been demonstrated in brain tissue after
ischemic stroke [50,51]. Altogether, Fas might be an indicator of hypertension-induced end-
organ damage.
Interestingly, a connection between Fas and Olr1 has been suggested, since Olr1 was shown
to facilitate an oxLDL-induced augmentation of Fas-mediated apoptosis [52]. This correlates
with the increased expression of the genes in the hypertensive cerebral arteries.
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Conclusions
This exploratory study is the first to reveal that Postn, Fas, Vldlr, Mmp2, Timp1, Serpine1
and Olr1 could be possible genetic mediators of the vascular changes in hypertensive cere-
bral arteries. Interestingly, previous research supports a connection between several of the
verified genes and the vascular changes associated with hypertension which highlights the
importance of the reported hypertension-susceptible genes to the current knowledge of
molecular mechanisms during hypertension. The strength of this study is that it is con-
ducted in hypertensive cerebral arteries since hypertension contributes to vascular changes
and is a risk factor of other cerebrovascular diseases such as stroke. Some of the genes have
previously been implicated in secondary complications to hypertension. This study supports
the selection of key genes to investigate in the future research of hypertension-induced end-
organ damage.
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S1 Fig. Genes with increased expression in MCAs from hypertensive compared to normo-
tensive rats. Scatter plot of (A) Postn, (B) Olr1, (C) Fas, (D) Vldlr, (E) Mmp2, (F) Timp1 and
(G) Serpine 1 expression from SHRs and WKY rats. ΔCt values are plotted on the y-axe by a
logarithmic scale. Data is expressed as median ± interquartile range, and n represents the num-
ber of rats. P-value <0.05 is considered statistical significant.
(TIF)
S2 Fig. Genes with no expressional changes in MCAs between hypertensive and normoten-
sive rats. Scatter plot of (A) Cd34, (B) Ptgs2 and (C) Mmp11 expression in middle cerebral
arteries from SHRs and WKY rats. ΔCt values are plotted on the y-axe by a logarithmic scale.
Data is expressed as median ± interquartile range, and n represents the number of rats. P-
value <0.05 is considered statistical significant.
(TIF)
S3 Fig. Western blot membrane of LOX1 and β-ACTIN. Western blot membrane with
(A) LOX1 and (B) β-ACTIN. The molecular marker is marked with a black square. Before
incubation with primary antibodies the membrane was cut just before 71 kDa and 28 kDa.
Sample in lane 2 and 3 are samples used to test different antibodies for the other membrane
pieces. (A) According to Abcam, LOX1 proform was detected at 50 kDa and LOX1 mature
form was detected at 31 kDa. However, the LOX1 proform in the antibody images from
Abcam homepage seems to be at 45 kDa and not 50 kDa according to the molecular marker
which correlate with the band around 48 kDa on our membrane. The other bands are unspe-
cific binding which could be due to the many different cell types in the cerebral arteries.
(B) According to Sigma, β-ACTIN was detected at 42 kDa. The membrane was stripped before
incubation with β-ACTIN but there might a vague LOX1 binding left on the membrane. We
used LOX1 and β-ACTIN antibodies from two different species.
(TIF)
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